PubMed · 6849560
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M V Dahl, W P Jordan. 1983. Topical steroids and patch tests.. https://doi.org/10.1001/archderm.119.1.3b
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The effect of permethrin impregnated plastic strips (Die No Mite Strips) was evaluated on Dermanyssus gallinae populations in aviary systems for layers in Sweden. Two application strategies of the strips were tested: (A) attached in the housing system, allowing the birds to rub against the strips and thereby get the acaricide released onto their plumage, and (B) attached out of reach of the hens, at two different sites (perches and egg-belt lids) of the inner surfaces of the system, where the mites sheltered during the day. On two farms with 2030 (A) and 3384 (B) hens, and existing mite populations, strips were mounted for 20 and 10 weeks, respectively, and mite numbers were monitored by traps. With application A an overall mite reduction of 53% was observed, while with B the mean mite numbers decreased by 39% at the perches and 92% at the egg-belt lid. The strips were originally designed for caged hens afflicted by ectoparasites that stay on the host for most of their life cycle. However, since D. gallinae spends most of its time off the host, it was not possible to control the parasite with application A. Resistance tests performed on mites from both treated and control compartments where application A was used showed no indication of resistance to permethrin, while 95% of the mites survived a 48 h exposure to the compound where application B was performed. Thus, permethrin resistant mites appeared to be the main reason for the failure to control D. gallinae with application B.
The effect of dermal application of halofuginone-an inhibitor of collagen type I synthesis-on skin collagen and collagen alpha1(I) gene expression in an animal model of scleroderma and chronic graft versus host disease (cGvHD) was evaluated. Halofuginone-containing cream was applied on the tight-skin mouse (Tsk) and skin biopsies were taken for collagen staining by sirius red and for collagen alpha1(I) gene expression by in situ hybridization. In addition, cell proliferation was evaluated by immunostaining for proliferation cell nuclear antigen (PCNA) alone or in combination with collagen alpha1(I) probe. The number of mast cells was assessed by toluidine blue. Dermal application of halofuginone (0.01%) for 60 days was as good as systemic administration (1 microg/mouse/day) in reducing collagen alpha1(I) gene expression in skin biopsy and almost as good in reducing skin width. Halofuginone was stable and effective only at acidic pH. The effect of halofuginone (0.03%) was time-dependent. After 40 days of daily treatment, a significant reduction in the collagen alpha1(I) gene expression was observed and further decrease was observed after 60 days. The reduction in collagen alpha1(I) gene expression and the reduction in the proliferation of dermal fibroblasts probably occur in the same subset of cells. No effect of halofuginone on the proliferation of keratinocytes or on mast cell number was observed. These results suggest that target-oriented application of halofuginone may become a novel therapy for fibrotic disorders in general and for scleroderma in particular.
Myringotomy and tube insertion, a common pediatric surgical procedure, is frequently complicated by purulent otorrhea. Many otolaryngologists routinely use topical antibiotics as prophylaxis against post-tympanostomy otorrhea. The aminoglycosides (neomycin sulfate, tobramycin and gentamicin) contained in commonly used topical antibiotics as well as components of the solutions have been shown to be ototoxic in animal studies. Although little reported evidence of ototoxicity in humans exists, sporadic reports of sensorineural hearing loss linked to topical antibiotic use do exist, and the potential for sensorineural hearing loss must be considered. The purpose of this study is to compare the rate of post-tympanostomy otorrhea in a double-blinded randomized trial using either topical Ciprofloxacin, with no reported ototoxicity, or Cortisporin as prophylaxis. One hundred patients (200 ears) between ages 7 months and 11 years with a diagnosis of recurrent otitis media or chronic otitis media undergoing tympanostomy tube insertion were randomized into two equal groups. Three drops of either drop A or B were placed into each ear at the time of tube insertion and then three times daily for 3 days. Patients were examined at 3 weeks and details of otorrhea were obtained. The rate of otorrhea was analyzed using chi-square. The overall rate of otorrhea was 39 ears (19.5%), 17 (17%) ears for the Cortisporin group and 22 (22%) for the Ciprofloxacin group. The difference in rate of otorrhea was not statistically significant (P=0.372, 95% confidence interval equals -6-16%). Our data suggest that topical Cortisporin offers no benefit over Ciprofloxacin for post-operative otorrhea prophylaxis. Therefore we recommend topical quinolone prophylaxis, which should eliminate concerns about ototoxicity, without sacrificing efficacy.